BIMZELX
As listed in the register: BIMZELX
320 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Bimekizumab
- Made by
- Ucb Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Bimzelx). It describes the substance, not this exact product.
Bimekizumab-bkzx is a humanized immunoglobulin IgG1/ κ monoclonal antibody with two identical antigen binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex.
IL-17A and IL-17F are naturally occurring cytokines that are involved in normal inflammatory and immune responses.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-06-16
Safety of the active substance
From the US prescribing label for the same active substance (Bimzelx). It describes the substance, not this exact product.
The most commonly reported infections were comparable to those reported in subjects with PSO.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Ucb Canada Inc |
|---|---|
| Active substance | Bimekizumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 320 mg |
| Form | solution |
| Classification | L04AC21 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | SCHEDULE D · PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02553627 |
| DPD drug code | 104254 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution4 products
160 mg2
160 mg · 2 companies
320 mg2
320 mg · 2 companies
- Ucb Canada Inc · this page
- Ucb Canada Inc
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.